(Bloomberg) -- Pfizer Inc.’s Covid-19 pill received backing from the European Union’s drugs regulator, offering a tool to manage coronavirus infections at home and ease the burden on hospitals.

The European Medicines Agency’s expert committee recommended granting a conditional marketing authorization for the antiviral, called Paxlovid, for adults with Covid at risk of developing severe illness. The agency had already said in December that the treatment could be used by adults, in advance of formal approval.

The prospect of a pill that can be taken at home at the first sign of symptoms is sparking optimism about the course of the pandemic, especially amid evidence that the omicron variant causes less severe disease. Paxlovid, which works by binding to an enzyme to stop the virus from replicating, reduced hospitalization and death among high-risk patients by 89% in a trial of 1,219 unvaccinated individuals. 

Pfizer has since said that laboratory testing has showed the treatment is effective against the omicron variant.

The U.K.’s regulator cleared Paxlovid at the end of last year, and the drug also has emergency-use authorization in the U.S.

©2022 Bloomberg L.P.